510(k) · Cleared
Recalled · Class II · 2015D-10 Hemoglobin A1C Program; D-10 Dual Program
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Bio-Rad Laboratories, Inc. · LCP Assay, Glycosylated Hemoglobin
Cleared on Jan 20, 2006 as substantially equivalent to K031043 (Bio-Rad Laboratories, Inc., 2003) and 1 other predicate after a 17-day review. Its family tree reaches back 3 generations to 1993. It has been recalled once.
- Decided
- Jan 20, 2006
- Review
- 17 days
- Class
- Class II
- Product code
- LCP
- Recalls
- 1
- Predicates
- 2
Its longest line of descent runs back 3 generations to K926469 (1993). 6 ancestors in all, the oldest K924122 (1993). No later device cites it as a predicate yet.
- Root · 3 generations backK926469 Variant (TM) Hemoglobin a 1C ProgramBio-Rad · 1993
- 2 generations backK984268 Variant II Hemoglobin A1C ProgramBio-Rad · 1998 · Recalled
- 1 generation backK031043 D-10 Hemoglobin A1CBio-Rad Laboratories, Inc. · 2003 · Recalled
- This deviceK060001 D-10 Hemoglobin A1C Program; D-10 Dual ProgramBio-Rad Laboratories, Inc. · 2006
View FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −3 | K926469 | Variant (TM) Hemoglobin a 1C Program | Bio-Rad | 1993 | — |
| −2 | K984268 | Variant II Hemoglobin A1C Program | Bio-Rad | 1998 | 2 |
| −1 | K031043 | D-10 Hemoglobin A1C | Bio-Rad Laboratories, Inc. | 2003 | 6 |
| 0 (this device) | K060001 | D-10 Hemoglobin A1C Program; D-10 Dual Program | Bio-Rad Laboratories, Inc. | 2006 | — |
Other ancestors by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 1993 | 1 | 0 |
| 1999 | 1 | 0 |
| 2004 | 1 | 0 |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in LCP? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new LCP device
- #1 K221326 Nova Allegro HbA1c Assay, Nova Allegro Analyzerscore 9.6 · 5 generations · no Class I recall
- #2 Held for the reportin the report
- #3 Held for the reportin the report
What was it cleared against? (2)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | K031043 | D-10 Hemoglobin A1CSummary page 2…icate Devices: D-10 Hemoglobin Alc Program Bio-Rad Laboratories, Inc. [K031043, August 27, 2003] D-10 Dual Program Bio-Rad Labora… | 2003 |
| * | K041444 | Bio-Rad D-10 Dual ProgramSummary page 2…2003] D-10 Dual Program Bio-Rad Laboratories, Inc [K041444, June 9, 2004] Bio-Rad Laboratories, Inc 4-A-I Indications for Use Statements and Intended… | 2004 |
What descends from it?
No later submission names this one as a predicate yet.
Has anything in its family been recalled? (0 Class I)
Recalls of this device
| Date | Class | Recall | Root cause | Reason |
|---|---|---|---|---|
| Dec 15, 2015 | Class II | Z-0695-2016 | Software design | On a rare occasion, there is a potential to assign a patient result to an incorrect sample ID when running in D10 Rack Loader configuration. |
No ancestor or descendant has a Class I recall.
What does this lineage say?
- The line of descent spans 13 years and passes through 2 companies; a new generation was cleared every 4.7 years on median.
- 5 of the 6 ancestors have a recall of any class.
- 1 other device also cites its predicate K031043.
How does its category compare?
All LCP devicesLCP Assay, Glycosylated Hemoglobin: FDA decisions, review times, recalls and adverse event reports over 20 years.
FDA decisions per year · LCP
1in 2024
2026 to Oct 25, outlined.
Median 510(k) review, days · LCP
269in 2019
Receipt to decision; years with fewer than 3 clearances left blank.
Recalls per year · LCP
1in 2025
Class I (0 since 2007) Class II/III not classified
Adverse event reports per year · LCP
22in 2025
MAUDE reports naming product code LCP, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 7 | 133 | 1 | 5 |
| 2008 | 5 | 206 | 3 | 11 |
| 2009 | 6 | 158 | 6 | 15 |
| 2010 | 2 | — | 5 | 4 |
| 2011 | 10 | 176 | 51 | 27 |
| 2012 | 9 | 143 | 0 | 51 |
| 2013 | 2 | — | 4 | 193 |
| 2014 | 8 | 127 | 2 | 182 |
| 2015 | 3 | 239 | 2 | 64 |
| 2016 | 2 | — | 6 | 29 |
| 2017 | 5 | 218 | 1 | 149 |
| 2018 | 2 | — | 1 | 1,911 |
| 2019 | 4 | 269 | 0 | 114 |
| 2020 | 1 | — | 0 | 13 |
| 2021 | 0 | — | 0 | 7 |
| 2022 | 0 | — | 1 | 8 |
| 2023 | 2 | — | 0 | 27 |
| 2024 | 1 | — | 1 | 39 |
| 2025 | 0 | — | 1 | 22 |
| 2026 | 0 | — | 0 | — |
What is it indicated for?
Measurements of percent HbAlc are effective in monitoring long-term glucose control in individuals with diabetes mellitus.
Measurement of percent HbA 2 and HbF are used for evaluation f3 - thalassemia, a hereditary hemolytic anemia.
Detection of hemoglobin variants such as S, C, D and E are effective in presumptive identification.
Indications for use as stated in the FDA summary.
https://510kreport.com/device/K060001 · printed Nov 6, 2026
Cite this page
510(k) Report. “K060001: D-10 Hemoglobin A1C Program; D-10 Dual Program.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K060001
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026